Navigation Links
ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
Date:8/8/2008

By Kathleen J. Burkhalter

BOSTON, Aug. 8 /PRNewswire/ -- Francis, 50, never imagined that drinking a high anti-oxidant fruit beverage every day could help protect his health -- in just 1 week. That's what he found out after participating in a clinical trial near his home in Los Angeles, Calif.

A new study conducted by Bell Ventures, shows that after just 7 days, platelet aggregation, a known indicator of cardiovascular disease (CVD), was significantly reduced in many of the participants who took the anti-oxidant product, ViaViente, twice a day.

David Bell, President of Bell Ventures, said, "These results are important because they show how a natural anti-oxidant and anti-inflammatory product like ViaViente can help protect against one of our most serious health concerns."

Health experts recommend a daily intake of anti-oxidants, especially in their natural form. Oxidative stress causes damage to cells and contributes to aging and disease. Anti-oxidants combat effects of oxidative stress such as inflammation.

A recent independent report, A Consumer Conscious Look at Six Premium Anti-Oxidant Products, by Frank Ervolino, ND, shows that ViaViente outperformed other popular products using ORAC -- an industry standard for anti-oxidant testing. This is an important indication of quality and potential benefits.

Clinical research shows the connection between what's in the product and actual outcomes in human health.

The ViaViente study takes direct aim at the benefits to cardiovascular health of consuming a non-drug, natural food product. It correlates the consumption of ViaViente to platelet inhibition -- a marker of CVD.

Why is cardiovascular health so important? The American Heart Association reports that approximately 80 million people in the United States have CVD; nearly 2,400 people die of CVD every day; more people die from CVD than from cancer, auto accidents, and Type 2 diabetes com
'/>"/>

SOURCE Bell Ventures LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...July 2 Acura Pharmaceuti...als, Inc. (NYSE: KG ) announced today that the U...a Complete Response Letter regarding the New Drug ...nd niacin, USP) Tablets CII, an immediate release ...ere pain. , , (Logo: http://www.newscom.co...
(Date:6/30/2009)...re/ -- If you have been eating Garlic to keep the ...e there is absolutely no scientific evidence that ...ying garlic has plenty of evidence to prove it kee...rassy lawns is not as strange as it seems. Mosquit...c. is being used successfully by city parks, golf ...
(Date:6/30/2009)...Calixa Therapeutics Inc. today announced the initi...tients with complicated urinary tract infections. ...losporin antibiotic with excellent in vitro and ... , including drug resistant isolates. Calixa is i...serious bacterial infections in hospitalized patie...
(Date:6/29/2009)...tients achieved primary and secondary endpoints ,... AcelRx Pharmaceuticals, Inc. today announced posi...y evaluating the safety and efficacy of its ARX-01...te post-operative pain in patients requiring opioi...acebo, patients receiving ARX-01 Sufentanil NanoTa...
Breaking Medicine Technology:Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 3Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc. 2Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director 13088 1Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director 13088 2Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference 3616 1China Medical Technologies Reports Third Quarter Financial Results 13079 1China Medical Technologies Reports Third Quarter Financial Results 13079 2China Medical Technologies Reports Third Quarter Financial Results 13079 3China Medical Technologies Reports Third Quarter Financial Results 13079 4China Medical Technologies Reports Third Quarter Financial Results 13079 5China Medical Technologies Reports Third Quarter Financial Results 13079 6China Medical Technologies Reports Third Quarter Financial Results 13079 7China Medical Technologies Reports Third Quarter Financial Results 13079 8China Medical Technologies Reports Third Quarter Financial Results 13079 9China Medical Technologies Reports Third Quarter Financial Results 13079 10China Medical Technologies Reports Third Quarter Financial Results 13079 11China Medical Technologies Reports Third Quarter Financial Results 13079 12As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years Technology will be Called upon to Stem the Tide 13074 1As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years Technology will be Called upon to Stem the Tide 13074 2
...provide a new therapeutic approach for the treatme...ITY, April 17, 2007 /PRNewswire-FirstCall/ - AEter...utical company,focused on endocrine therapy and on...ivo data for its growth hormone-releasing,hormone ... American,Association for Cancer Research (AACR) A...
...y announced, primary endpoint not met; plausibly,c...ent with ERBITUX,-, NEW YORK, April 16, 2007 /PRNe...and Bristol-Myers Squibb Company today,announced d...,open-label, multi-center Phase III trial - compa...notecan alone in patients with,metastatic colorect...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
(Date:7/2/2009)...YERS, Fla., July 2 Acet...counter and prescription medicines to help relieve...aminophen by a brand name, Tylenol and prescriptio...visory committee for the FDA met on June 30, 2009 ...f acetaminophen. The committee voted 20-17 to urg...
(Date:7/2/2009)...Health one of 63 businesses honored in Washington,...-USNewswire/ -- Texas Health Resources has recei...ard from the National Business Group on Health. ,.../20090702/DC41773LOGO ) , , The award recogn...ive programs that promote a healthy workplace and ...
(Date:7/2/2009)...ores weight problems faced by youngsters with the ...News) -- Children with type 1 diabetes are more li...se, increasing their risk of serious health compli... a major study that explored the weight problems f...ss common form of the disease that usually shows u...
(Date:7/2/2009)...statistical and biological issues need to be addre...for early detection of cancer, according to a comm...the National Cancer Institute . , The biomarker ...tests includes the identification of promising bio...d definitive evaluation of biomarkers for cancer s...
Breaking Medicine News(10 mins):Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Kids With Type 1 Diabetes Often Overweight 2
...g syndrome is a disorder of neurological origin. T.../ legs becomes strong even if the person is statio...er from sensations like burning or itching, or eve... These sensations are termed as paresthesias or dy...
...of University of Southern California, US had been ...asthma and smoking habit of mother and maternal gr... of families with children suffering from asthma r...her before, during and after the pregnancy. The hi...
...d Drug Administration (FDA) of US had warned the p...ertain drugs broadly called as atypical antipsycho...rugs, aripiprazole, olanzapine, quetiapine, risper...approved for the clinical treatment of schizophren...
... of a study on dietary minerals and their effects ...he diets of children may help them in increasing t...on the diets of Chinese children of age between 6 ...supplement of 20mg of zinc alone and the other gro...
Other Medicine News:
The Premier Anterior Cervical Plate System allows for axial load sharing bone screw translation along slots in the plate, while maintaining constrained fixation at the distal end of the construct. In
Cervive is an Anterior Cervical Plating System that has been engineered to provide flexibility and simplicity for the spinal surgeon, allowing replication of normal anatomical function and safe fixat
...compression plate acc. to Matzen is used for the a...with the exception of C0-C2. The implant provides ...the bone transplant has consolidated. The plate is...ible along the center line. It has instrument repo...
The Codman anterior cervical plate is designed for immediate internal fixation of the cervical spine following bone grafting procedures.
Medicine Products: